期刊论文详细信息
Cancers
Formulations for Intranasal Delivery of Pharmacological Agents to Combat Brain Disease: A New Opportunity to Tackle GBM?
Matthias van Woensel1  Nathalie Wauthoz3  Rémi Rosière3  Karim Amighi3  Véronique Mathieu4  Florence Lefranc4  Stefaan W. van Gool2 
[1] Laboratory of Experimental Neurosurgery and Neuroanatomy, KU Leuven, Leuven 3000, Belgium; E-Mail:;Laboratory of Pediatric Immunology, KU Leuven, Leuven 3000, Belgium; E-Mail:;Laboratory of Pharmaceutics and Biopharmaceutics, ULB, Brussels 1050, Belgium; E-Mails:;Laboratory of Toxicology, ULB, Brussels 1050, Belgium; E-Mails:
关键词: glioblastoma multiforme;    intranasal administration;    nose-to-brain delivery;    formulations;    nanoparticles;    drug delivery;    new therapy concept;   
DOI  :  10.3390/cancers5031020
来源: mdpi
PDF
【 摘 要 】

Despite recent advances in tumor imaging and chemoradiotherapy, the median overall survival of patients diagnosed with glioblastoma multiforme does not exceed 15 months. Infiltration of glioma cells into the brain parenchyma, and the blood-brain barrier are important hurdles to further increase the efficacy of classic therapeutic tools. Local administration methods of therapeutic agents, such as convection enhanced delivery and intracerebral injections, are often associated with adverse events. The intranasal pathway has been proposed as a non-invasive alternative route to deliver therapeutics to the brain. This route will bypass the blood-brain barrier and limit systemic side effects. Upon presentation at the nasal cavity, pharmacological agents reach the brain via the olfactory and trigeminal nerves. Recently, formulations have been developed to further enhance this nose-to-brain transport, mainly with the use of nanoparticles. In this review, the focus will be on formulations of pharmacological agents, which increase the nasal permeation of hydrophilic agents to the brain, improve delivery at a constant and slow release rate, protect therapeutics from degradation along the pathway, increase mucoadhesion, and facilitate overall nasal transport. A mounting body of evidence is accumulating that the underexplored intranasal delivery route might represent a major breakthrough to combat glioblastoma.

【 授权许可】

CC BY   
© 2013 by the authors; licensee MDPI, Basel, Switzerland.

【 预 览 】
附件列表
Files Size Format View
RO202003190034144ZK.pdf 507KB PDF download
  文献评价指标  
  下载次数:8次 浏览次数:15次